These findings suggest that future strategies for therapeutic intervention in CMT patients, such as base editing gene therapy, may be able to directly target SORD mutations, like the c.757delG variant, to reverse the symptoms associated with loss of sorbitol dehydrogenase function. Here, SORD is linked to Charcot-Marie-Tooth disease.